Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), an investigational, once-weekly, low-dose hormonal contraceptive patch, has been...
Toggle Summary Agile Announces Dosing of First Patients in Twirla(R) Phase 3 SECURE Study
PRINCETON, N.J., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the first patients have been dosed in its...
Toggle Summary Agile CEO Presents at Needham Healthcare Conference
Toggle Summary Agile Initiates Phase 3 SECURE Study for Twirla(TM)
Twirla (AG200-15) is a Novel Low-Dose Combined Hormonal Contraceptive Patch Designed Using the Company's Proprietary Transdermal Skinfusion ® Technology Confirmatory SECURE Study To Build Upon Data From Previous Phase 3 Studies in Support of the Company's New Drug Application to the U.S....
Toggle Summary Agile President and CEO Appointed as an Officer of the Dean's Advisory Board, Drexel University, Lebow College of Business
Agile President and CEO Appointed as an Officer of the Dean's Advisory Board, Drexel University, Lebow College of Business The Dean’s Advisory Board elected five new members and three new officers at its fall meeting – its first held in Gerri C. LeBow Hall....
Toggle Summary Agile Therapeutics Added to Membership of Russell 2000(R), 3000(R) and Global Indexes
PRINCETON, N.J., June 30, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that its stock has been selected for addition to...
Toggle Summary Agile Therapeutics Announces $20 Million Private Placement and Provides Clinical Trial Update
PRINCETON, New Jersey , Jan. 20, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has entered into a definitive...
Toggle Summary Agile Therapeutics Announces $7.8 Million Private Placement
PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares...
Toggle Summary Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal...
Toggle Summary Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion®
Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System...
Shadow